Valuation: Matinas BioPharma Holdings, Inc.

Market Cap 1.79M 1.61M 1.49M 1.35M 2.52M 170M 2.55M 17.81M 7.07M 89.24M 6.73M 6.58M 283M P/E 2024
-0.1x
P/E 2025 -0.29x
Enterprise Value -852K -765K -706K -641K -1.2M -80.97M -1.21M -8.47M -3.36M -42.44M -3.2M -3.13M -135M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
76.25%
Yield 2024 *
-
Yield 2025 -
1 day-1.37%
1 week+18.75%
Current month-29.22%
1 month-28.66%
3 months-58.93%
6 months-79.81%
Current year-79.47%
1 week 1.52
Extreme 1.52
1.9
1 month 1.47
Extreme 1.4693
3.15
Current year 1.47
Extreme 1.4693
13.6
1 year 1.47
Extreme 1.4693
22.2
3 years 1.47
Extreme 1.4693
322.5
5 years 1.47
Extreme 1.4693
945
10 years 1.47
Extreme 1.4693
2,992.5
Manager TitleAgeSince
Chief Executive Officer 52 16/03/2018
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 52 14/03/2025
Director/Board Member 61 05/02/2025
Director/Board Member 55 11/03/2025
Date Insider Type Main position Quantity % Market Cap. Importance
4/30/25 A Free

Chief Executive Officer

70,100 1.3780%
4/30/25 A Free

Director

11,600 0.2280%
4/30/25 A Free

Director

11,600 0.2280%
Change 5-day change 1-year change 3-year change Capi.($)
-1.37%+18.75%-91.71%-98.85% 1.79M
+0.65%-3.56%+33.53%+60.50% 63.48B
+2.25%+1.98%+12.61%+83.40% 54.55B
-1.10%+1.15%+10.63%+102.50% 53.59B
+2.20%+1.07%+28.17%+57.81% 44.75B
+2.52%-2.83%+18.52%+101.23% 41.62B
+1.14%-2.97%+224.07%+927.30% 39.91B
+0.64%-3.85%+11.71%+45.57% 32.47B
+28.73%+47.37%+106.75%+93.92% 26.7B
+3.72%-7.45%+24.25%-2.99% 23.36B
Average +4.17%+0.39%+37.85%+137.04% 38.04B
Weighted average by Cap. +3.46%-0.29%+47.73%+161.95%

Financials

2024 2025
Net sales - -
Net income -24.25M -21.77M -20.1M -18.22M -34.06M -2.3B -34.48M -241M -95.69M -1.21B -91.03M -89.08M -3.83B -10.34M -9.28M -8.57M -7.77M -14.53M -983M -14.71M -103M -40.82M -515M -38.83M -38M -1.63B
Net Debt -4.39M -3.94M -3.64M -3.3M -6.17M -417M -6.24M -43.62M -17.32M -219M -16.48M -16.13M -693M -2.64M -2.37M -2.19M -1.99M -3.72M -251M -3.76M -26.28M -10.44M -132M -9.93M -9.72M -418M
Projected Income Statement - Annual - Matinas BioPharma Holdings, Inc.
Logo Matinas BioPharma Holdings, Inc.
Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering therapies using its lipid nanocrystal (LNC) platform delivery technology. Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 has completed a Phase II encochleated oral amphotericin for cryptococcal meningitis trial (EnACT) study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options.
Employees
2
Date Price Change Volume
28/10/26 $1.805 -1.37% 3,691
27/10/26 $1.830 +10.24% 27,801
26/10/26 $1.660 -2.39% 49,734
23/10/26 $1.701 -0.55% 11,289
22/10/26 $1.710 +12.50% 48,426

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Matinas BioPharma Holdings, Inc.
  1. Stock Market
  2. Stocks
  3. MTNB Stock